Search Results for “GSK ” – Page 8 – media

GSK opens new aluminium salts facility in Scotland

Being set to supply ingredients for around 400 million vaccines a year, a new £44 million aluminium salts facilityhas been officially opened by GlaxoSmithKline in Montrose, Scotland.
- Source: news.open-medical
- 619
- August 17, 2017
aluminium salt Company Insight HIV ingredient respiratory vaccine
GSK delivers further progress in Q2 and sets out new priorities for the Group

GSK delivers further progress in Q2 and sets out new priorities for the Group
- Source: www.gsk.com/
- 378
- August 4, 2017
Company Insight
GSK tests mepolizumab for nasal polyps

GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
- Source: Pharmtimes
- 783
- June 28, 2017
Clinical Trials EU mepolizumab
GSK tests mepolizumab for nasal polyps

GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
- Source: pharmatimes
- 757
- June 28, 2017
asthma Company Insight EU surgery
GSK’s inhaler improves asthma control in ‘real world’ study

GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
- Source: pharmatimes
- 580
- May 8, 2017
asthma Company Insight therapy
Domestic lupus erythematosus drugs sold for 6 billion!

According to media statistics, in the first half of 2024 alone, at least 32 innovative pharmaceutical companies in China successfully completed BD projects, achieving cross-border expansion and involving transaction amounts exceeding 20 billion US dollars, with a significant increase in quantity compared to previous years. And this trend continues into the second half of the year, with domestic innovative pharmaceutical companies such as Ruige Pharmaceutical, Jiahe Biotechnology, Tongrun Biotechnology, and Anmai Biotechnology all having significant BD transactions. Recently, a domestic innovative pharmaceutical company that has only been established for eight years and currently has only a few pipelines under research sold one of its products, BD, for a sky high price. GlaxoSmithKline (GSK) has officially announced that it has reached an acquisition agreement with Chinese innovative pharmaceutical company Chimagin Biosciences for the three specific antibody CMG1A46. Accordingly, GSK will make a prepayment of $300 million to Enmu Biotechnology to acquire ...
- Source: drugdu
- 48
- November 12, 2024
5 innovative drugs included in breakthrough treatment varieties

Breakthrough treatment varieties refer to innovative drugs or improved new drugs used to prevent and treat diseases that seriously endanger life or seriously affect quality of life, and for which there are no effective prevention and treatment methods or sufficient evidence to show significant clinical advantages compared to existing treatment methods. After obtaining this recognition, it can accelerate the review process, accelerate the drug development process, and solve the unmet clinical needs of patients. In the past October, the CDE official website plans to include 5 breakthrough therapy varieties, including 1 therapeutic vaccine, 3 ADC drugs, and 1 monoclonal antibody drug. The following are introductions to 5 innovative drugs for reference only. 1. TVAX-008: Hepatitis B On October 14th, Nanjing Yuanda Weixin Biopharmaceutical Co., Ltd. TVAX-008 applied to be included in the breakthrough treatment category, suitable for the treatment of chronic hepatitis B virus (HBV) infection. TVAX-008 is a therapeutic ...
- Source: drugdu
- 70
- November 6, 2024
RNA editing pioneers fought a comeback

“CRISPR gives way, RNA editing therapies are going to speed up.” This is the title of an article published in “Nauter” in February this year (“Move over, CRISPR: RNA-editing therapies pick up steam”). RNA editing technology, which is coming to the fore, is seen as having the potential to surpass CRISPR due to its safer and more flexible characteristics. The technology is in its infancy, and the bets of MNCs such as Eli Lilly and GSK have once pushed its popularity to a climax. However, Wave, an RNA editing pioneer founded in 2012, took more than 10 years to push its first RNA editing project WVE-006 into clinical trials. During this period, due to the clinical failure of other nucleic acid drugs, Wave’s stock price fell from a high of US$56 per share to around US$1 per share, and market expectations were no longer there. After years of silence, a ...
- Source: drugdu
- 74
- October 23, 2024
Milepost! The first RNA editing therapy releases clinical data

On October 16th, Wave Life Sciences released positive mechanistic evidence data from the Ib/IIa RestorAATion-2 study of RNA editing therapy WVE-006 for the treatment of alpha-1 antitrypsin deficiency (AATD). This is the first RNA editing therapy to release clinical data. AATD is a genetic disease caused by mutations in the SERPINA1 gene, which encodes alpha-1 antitrypsin (AAT), the most abundant protease inhibitor in human serum. Patients with homozygous protease inhibitor gene mutation type (Pi * ZZ) AATD are unable to naturally produce wild-type alpha-1 antitrypsin (M-AAT) protein. Therefore, after receiving WVE-006 treatment, patients can produce M-AAT protein in their bodies, which confirms the successful editing of mutant Z-AAT mRNA. In addition, restoring 50% of M-AAT levels will be consistent with the heterozygous “MZ” genotype, resulting in a lower risk of AATD lung disease and liver disease. The data released this time comes from the 200mg single dose cohort of RestorAATion-2 ...
- Source: drugdu
- 78
- October 22, 2024
RNA editing pioneers fought a comeback

This is the title of an article published in Nauter in February this year (Move over, CRISPR: RNA-editing therapies pick up steam). RNA editing technology, which is coming to the fore, is seen as a potential to surpass CRISPR due to its safer and more flexible characteristics. The technology is in its infancy, and the bets of MNCs such as Eli Lilly and GSK have once pushed its popularity to a climax. However, Wave, an RNA editing pioneer founded in 2012, took more than 10 years to push its first RNA editing project WVE-006 into clinical trials. During this period, due to the clinical failure of other nucleic acid drugs, Wave’s stock price fell from a high of US$56 per share to around US$1 per share, and market expectations were no longer met. After years of silence, a counterattack driven by clinical data is taking place. On October 16, Wave ...
- Source: drugdu
- 75
- October 19, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.